Search Results - "Caudle, KE"

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update by Johnson, JA, Caudle, KE, Gong, L, Whirl‐Carrillo, M, Stein, CM, Scott, SA, Lee, MT, Gage, BF, Kimmel, SE, Perera, MA, Anderson, JL, Pirmohamed, M, Klein, TE, Limdi, NA, Cavallari, LH, Wadelius, M

“…This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy by Moriyama, B, Obeng, A Owusu, Barbarino, J, Penzak, SR, Henning, SA, Scott, SA, Agúndez, JAG, Wingard, JR, McLeod, HL, Klein, TE, Cross, SJ, Caudle, KE, Walsh, TJ

“…Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors by Hicks, JK, Bishop, JR, Sangkuhl, K, Müller, DJ, Ji, Y, Leckband, SG, Leeder, JS, Graham, RL, Chiulli, DL, LLerena, A, Skaar, TC, Scott, SA, Stingl, JC, Klein, TE, Caudle, KE, Gaedigk, A

“…Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing by Birdwell, KA, Decker, B, Barbarino, JM, Peterson, JF, Stein, CM, Sadee, W, Wang, D, Vinks, AA, He, Y, Swen, JJ, Leeder, JS, van Schaik, RHN, Thummel, KE, Klein, TE, Caudle, KE, MacPhee, IAM

“…Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron by Bell, GC, Caudle, KE, Whirl‐Carrillo, M, Gordon, RJ, Hikino, K, Prows, CA, Gaedigk, A, Agundez, JAG, Sadhasivam, S, Klein, TE, Schwab, M

“…5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonists are used in the prevention of chemotherapy- induced, radiation-induced and postoperative nausea and…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update by Saito, Y, Stamp, LK, Caudle, KE, Hershfield, MS, McDonagh, EM, Callaghan, JT, Tassaneeyakul, W, Mushiroda, T, Kamatani, N, Goldspiel, BR, Phillips, EJ, Klein, TE, Lee, MTM

“…The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA‐B*58:01 Genotype and Allopurinol Dosing was originally published in February…”
Get full text

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update by Hicks, J K, Sangkuhl, K, Swen, J J, Ellingrod, V L, Müller, D J, Shimoda, K, Bishop, J R, Kharasch, E D, Skaar, T C, Gaedigk, A, Dunnenberger, H M, Klein, T E, Caudle, K E, Stingl, J C

Get full text

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update by Hicks, JK, Sangkuhl, K, Swen, JJ, Ellingrod, VL, Müller, DJ, Shimoda, K, Bishop, JR, Kharasch, ED, Skaar, TC, Gaedigk, A, Dunnenberger, HM, Klein, TE, Caudle, KE, Stingl, JC

“…CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only…”
Get full text

Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group by Bank, PCD, Caudle, KE, Swen, JJ, Gammal, RS, Whirl‐Carrillo, M, Klein, TE, Relling, MV, Guchelaar, H‐J

“…Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group provide therapeutic recommendations for well‐known…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update by Crews, K R, Gaedigk, A, Dunnenberger, H M, Leeder, J S, Klein, T E, Caudle, K E, Haidar, C E, Shen, D D, Callaghan, J T, Sadhasivam, S, Prows, C A, Kharasch, E D, Skaar, T C

“…Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing by Gammal, RS, Court, MH, Haidar, CE, Iwuchukwu, OF, Gaur, AH, Alvarellos, M, Guillemette, C, Lennox, JL, Whirl-Carrillo, M, Brummel, SS, Ratain, MJ, Klein, TE, Schackman, BR, Caudle, KE, Haas, DW

“…The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation…”
Get full text

The Case for Pharmacogenetics‐Guided Prescribing of Codeine in Children by Gammal, Roseann S., Caudle, Kelly E., Quinn, Charles T., Wang, Winfred C., Gaedigk, Andrea, Prows, Cynthia A., Haidar, Cyrine E., Taylor, Annette K., Klein, Teri E., Sangkuhl, Katrin, Hankins, Jane S., Crews, Kristine R.

Get full text

Response to “Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped” ‐ The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole by Walsh, TJ, Moriyama, B, Penzak, SR, Klein, TE, Caudle, KE

Get full text

Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy by Crews, Kristine R, Caudle, Kelly E, Dunnenberger, Henry M, Sadhasivam, Senthilkumar, Skaar, Todd C

“…The underlying assumption for CPIC guidelines is that clinical high-throughput and preemptive genotyping will become common practice and clinicians will…”
Get full text